Moderna (NASDAQ:MRNA) Stock, Quote.Headers.trade-ideas

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Jim Cramer Photo by s_bukley on Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

FSLR

MRNA

POWL

Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and Powell Industries as buys.

Jim Cramer Labels Moderna A &#39;Big Disappointment,&#39; But Suggests Doubling Down On Another Pharma Powerhouse

Wall-Street-dall

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

ABNB

SPDR Dow Jones Industrial Average ETF Trust

ENPH

S&amp;P 500 hits new record highs amidst expectations for Fed interest rate decision. Small-cap stocks outperform, while uncertainty remains.

S&amp;P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday&#39;s Top 5 Gainers

Wall-Street-ai5

Sector ETFs

Retail Sales

Small Cap

Federal Reserve

$BTC

Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committee (FOMC) kicked off its two-day meeting, expected to deliver the first interest rate cut in over four year

Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What&#39;s Driving Markets Tuesday?

Moderna Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$65.0K</td>
<td>37.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/27/24</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>814</td>
<td>482</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$130.00</td>
<td>$25.3K</td>
<td>972</td>
<td>303</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.50</td>
<td>$196.0K</td>
<td>7</td>
<td>201</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$62.50</td>
<td>$90.0K</td>
<td>1.0K</td>
<td>200</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$128.00</td>
<td>$32.6K</td>
<td>6</td>
<td>200</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$105.3K</td>
<td>561</td>
<td>174</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$155.00</td>
<td>$55.5K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$380.00</td>
<td>$98.7K</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>RPRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$50.2K</td>
<td>43</td>
<td>54</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 485 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $65.0K, with a price of $325.0 per contract. There were 37533 open contracts at this strike prior to today, and today 2165 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bullish sentiment. It expires in 9 day(s) on September 27, 2024. Parties traded 104 contract(s) at a $70.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $26.2K, with a price of $252.0 per contract. There were 814 open contracts at this strike prior to today, and today 482 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with bullish sentiment. It expires in 30 day(s) on October 18, 2024. Parties traded 59 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $430.0 per contract. There were 972 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we notice a put option trade that happens to be neutral, expiring in 485 day(s) on January 16, 2026. This event was a transfer of 200 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $196.0K, with a price of $980.0 per contract. There were 7 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option trade that happens to be bullish, expiring in 121 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $90.0K, with a price of $450.0 per contract. There were 1039 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with bearish sentiment. It expires in 2 day(s) on September 20, 2024. Parties traded 102 contract(s) at a $128.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $320.0 per contract. There were 6 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 121 day(s) on January 17, 2025. Parties traded 70 contract(s) at a $315.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $105.3K, with a price of $1505.0 per contract. There were 561 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding ALGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>), we observe a put option trade with bullish sentiment. It expires in 211 day(s) on April 17, 2025. Parties traded 150 contract(s) at a $155.00 strike. The total cost received by the writing party (or parties) was $55.5K, with a price of $370.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bearish, expiring in 275 day(s) on June 20, 2025. This event was a transfer of 30 contract(s) at a $380.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $98.7K, with a price of $3290.0 per contract. There were 10 open contracts at this strike prior to today, and today 57 contract(s) were bought and sold. 
• For RPRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>), we notice a call option trade that happens to be bullish, expiring in 211 day(s) on April 17, 2025. This event was a transfer of 54 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 43 open contracts at this strike prior to today, and today 54 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALGN

AMGN

EXAS

ILMN

RPRX

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and recommended <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">buying more of the stock.</a>
On Sept. 16, Cantor Fitzgerald analyst Louise Chen reiterated Pfizer with an Overweight rating and maintained a $45 price target.
&#8220;Six Flags (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), I don't know, it feels like it's two flags,&#8221; Cramer said. &#8220;This has just been a merger from hell. I'm not really into the stock.&#8221;
On Sept. 16, JPMorgan analyst Matthew Boss maintained Six Flags Entertainment with an Underweight rating and lowered the price target from $48 to $43.
Cramer said he likes First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), adding that it is an &#8220;up stock.&#8221;
On Sept. 16, BofA Securities analyst Julien Dumoulin-Smith maintained First Solar with a Buy and raised the price target from $320 to $343.
The &#8220;Mad Money&#8221; host said Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) is an &#8220;amazing&#8221; stock, and added that it's a &#8220;total winner.&#8221;
On Sept. 16, several analysts, including, Scotiabank, Evercore ISI Group and JPMorgan, raised their price targets on the stock.
Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has been a &#8220;big disappointment,&#8221; Cramer said.
Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.
&#8220;On a pullback, absolutely,&#8221; Cramer said when asked about Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>). &#8220;I think it's a winner.&#8221;
On Sept. 11, Vertiv named Frank Poncheri as chief human resources officer.
Cramer said Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) is a buy.
On July 30, Powell Industries reported better-than-expected third-quarter GAAP EPS and sales results.
Price Action:
<ul>
<li>Pfizer shares slipped 0.8% to settle at $29.83 on Tuesday.</li>
<li>Powell shares rose 2.5% to close at $174.44 during the session.</li>
<li>First Solar shares rose 2.9% to close at $239.98 during Tuesday's session.</li>
<li>Six Flags shares gained 2.3% to settle at $41.52.</li>
<li>Equity Residential shares fell 0.6% to close at $77.34 on Tuesday.</li>
<li>Moderna shares gained 4.1% to settle at $71.99 on Tuesday.</li>
<li>Vertiv shares gained 0.4% to close at $87.29.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>
Photo: s_bukley/Shutterstock.com

Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse

The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), hit fresh record highs during Tuesday morning trading and closed up 0.04%, marking its seventh consecutive day of gains, just ahead of the Federal Reserve&#8217;s highly <a href="https://www.benzinga.com/topic/interest-rates">anticipated interest rate decision.</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SPY&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPY</a> hit all-time highs today <a href="https://t.co/MxtEgTXErl">pic.twitter.com/MxtEgTXErl</a>
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1836051317464178892?ref_src=twsrc%5Etfw">September 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The performance of the index tracking the largest 500 U.S. companies by market capitalization was in line with other major indices. The Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the tech-heavy Nasdaq, and the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) both closed broadly flat for the day.
However, small-cap stocks outperformed their larger counterparts, as the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) finished 0.8% higher.
Policymakers gathered on Tuesday for the two-day Federal Open Market Committee (FOMC) meeting, with the interest rate decision expected on Wednesday at 2:00 p.m. ET.
Market expectations are mixed, with CME FedWatch data indicating a 65% chance of a 50-basis-point rate cut and a 35% chance of a smaller 25-basis-point cut. This level of uncertainty is unusual on the eve of a Fed decision.
Expectations for a larger rate cut fell slightly after August retail sales came in stronger than anticipated. Retail sales increased by 0.1% month-over-month, decelerating from July&#8217;s robust 1.1% growth but beating forecasts of a 0.2% decline.
The unexpected strength in consumer spending has cast some doubt on the need for a significant rate cut to support the economy.
An overwhelming consensus among Wall Street analysts anticipates a 25-basis-point cut, yet JPMorgan Chase stands among the outliers predicting a 50-basis-point reduction.
<h3 class="wp-block-heading">Tuesday&#8217;s Top 5 S&amp;P 500 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>1-day Return (%)</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>6.32</td>
</tr>
<tr>
<td>Hewlett Packard Enterprise Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NASDAQ">HPE</a>)</td>
<td>Information Technology</td>
<td>5.66</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>Health Care</td>
<td>4.05</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>4.00</td>
</tr>
<tr>
<td>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>)</td>
<td>Industrials</td>
<td>3.95</td>
</tr>
<tr>
<td>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)</td>
<td>Consumer Discretionary</td>
<td>3.86</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40908202/10-etfs-investors-secretly-bought-before-the-feds-make-or-break-interest-rate-cal">10 ETFs Investors Secretly Bought Before The Fed&#8217;s Make-Or-Break Interest Rate Call</a></li>
</ul>
Image created using artificial intelligence via Dall-E.

S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers

Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committee (FOMC) kicked off its two-day meeting, expected to deliver the first interest rate cut in over <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40878710/investors-bet-on-50-basis-point-rate-cut-wall-street-analysts-urge-caution-this-is-">four years on Wednesday.</a>
The session&#8217;s notable performers were small caps, with the Russell 2000 index surging about 1.3%, targeting its highest close since early August and outperforming larger-cap indices.
Among industries, solar, clean energy and regional banks led gains as traders eyed pockets of the markets that would benefit from lower interest rates.
On the macro front, August retail sales provided an upside surprise, growing by 0.1% month-over-month compared to <a href="https://www.benzinga.com/news/econ-s/24/09/40902634/retail-spending-remains-on-solid-footing-but-fed-must-weigh-rate-cuts-impact-on-workers-says-economi">the expected 0.2% decline</a>. This stronger-than-anticipated data slightly reduced the likelihood of a more aggressive 50-basis-point rate cut, with market-implied probabilities for such a move slipping from 67% to 63%, according to the CME FedWatch Tool.
Short-dated Treasury yields rose as expectations for a substantial rate cut moderated. Meanwhile, the dollar strengthened, gaining 0.2%. 
In the commodities market, gold retreated 0.7% from Monday&#8217;s record-high close. Oil prices increased by 1.3% following escalating geopolitical tensions in the Middle East.
Reports indicate a<a href="https://www.benzinga.com/etfs/specialty-etfs/24/09/40903888/simultaneous-pager-explosions-across-lebanon-leave-over-1-000-hezbollah-militants-wounded"> coordinated attack in Lebanon</a> led to thousands of pagers linked to Hezbollah militants being detonated, resulting in numerous casualties within the Iran-backed organization.
Additionally, Iran&#8217;s ambassador to Lebanon is reportedly injured, though the official responsibility for the attack remains unclaimed.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumped over 4%, buoyed by positive ETF inflows, signaling renewed investor interest in the digital asset space as interest rates shift. 
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,220.44</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,642.79</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,441.83</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,636.05</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:38 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091724&amp;t=be2bearmibe3na1">Benzinga Pro</a> platform:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $563.44.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% up to $417.61.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) also rose 0.1% to $473.60.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.2% to $220.28.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.2%. The Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) surged over 6% after receiving approval from Health Canada for its updated SPIKEVAX COVID-19 vaccine, designed to target the KP.2 sub-lineage of SARS-CoV-2 in individuals aged six months and older.</li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) climbed 3.5% following an upgrade from Bank of America, which raised its rating on the stock from Neutral to Buy and increased the price target from $200 to $300.</li>
<li>Hewlett Packard Enterprise Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) advanced nearly 5% after Bank of America also upgraded its rating from Neutral to Buy and boosted the price target from $21 to $24.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40904599/stock-of-the-day-will-apple-bring-the-market-down">Stock Of The Day: Will Apple Bring The Market Down?</a></li>
</ul>
The image was created using artificial intelligence MidJourney.

Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are moving higher on Tuesday after the company announced that Health Canada approved its updated <a href="https://www.benzinga.com//node/40903943">COVID-19 vaccine</a>.
What Happened: Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age or older.
The vaccine targets the KP.2 variant of COVID-19. The company plans to begin delivery of the vaccine to the Public Health Agency of Canada shortly.
The approval by Health Canada relies on a blend of manufacturing data, pre-clinical findings and earlier clinical, non-clinical and real-world evidence validating the efficacy and safety of Moderna&#8217;s mRNA vaccines for COVID-19.
&#8220;With the recent increase in COVID-19-infections,&nbsp;staying up to date with your COVID-19 vaccination remains one of the best ways to help protect yourself from severe illness,&#8221; said Dr. Shehzad Iqbal, country medical director, Moderna Canada.
How To Buy Moderna Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40904875/clearmind-medicine-files-international-patent-for-ibogaine-combination-therapy">Clearmind Medicine Files International Patent For Ibogaine Combination Therapy</a>
MRNA Price Action: At the time of publication, Moderna stock is moving 5.74% higher at $73.14 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

Movers

What's Going On With Moderna Shares Tuesday?

WIIM

Moderna shares are trading higher following reports suggesting that the company received Health Canada approval for an updated Covid-19 vaccine.

Biotech

Global

General

Moderna Gets Health Canada Approval For Updated Covid-19 Vax

Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.
The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.
In June, the U.S. CDC recommended <a target="_blank" href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html" rel="noreferrer noopener">using</a> updated 2024-2025 COVID-19 vaccines in individuals six months and older.
The FDA in August <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">granted emergency use</a> approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)/BioNTech SE's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), targeting the Omicron variant KP.2 strain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40347291/long-covid-remains-diagnostic-mystery-diagnosis-remains-elusive-national-institutes-of-health-fun" rel="noreferrer noopener">Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows</a>.
The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.
Earlier this month, the FDA granted Emergency Use Authorization to&nbsp;Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)&nbsp;protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40660946/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s" rel="noreferrer noopener">individuals aged 12 and older</a>.
The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.
The report <a target="_blank" href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997" rel="noreferrer noopener">adds</a> that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.
Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.
Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" rel="noreferrer noopener">heart attacks and strokes</a>.
Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40875211/bhp-group-sounds-alarm-on-copper-supply-ai-and-ev-growth-could-drive-prices-soaring-report" target="_blank" rel="noreferrer noopener">BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report</a>.</li>
</ul>
Image via Shutterstock

Government

Health Care

Legal

BNTX

NVAX

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $178 to $139.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $139

Barclays analyst Gena Wang maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Overweight and lowers the price target from $155 to $125.

Barclays Maintains Overweight on Moderna, Lowers Price Target to $125

AEMD

APDN

CMRX

GOVX

TNXP

VRAX

US To Stay Committed In Bringing Mpox Outbreak Under Control

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) shares plummeted 19.65% after the company revised the guidance <a href="https://www.benzinga.com//node/40814655" target="_blank" rel="noreferrer noopener">for the second half of FY24</a>.</li>
<li>Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) stock dived 17.31% after the company&#8217;s CFO noted intensifying credit challenges among <a href="https://www.benzinga.com//node/40800069" target="_blank" rel="noreferrer noopener">borrowers at a conference</a>. Several analysts cut the <a href="https://www.benzinga.com//node/40811970" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 11.26% after the company cut its R&amp;D expenses by $1.1 billion by 2027 and projected <a href="https://www.benzinga.com//node/40834547" target="_blank" rel="noreferrer noopener">2025 sales below expectations</a>. Many analysts <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered the price target</a>.</li>
<li>Humana Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock decreased 9.93%, probably after this week&#8217;s <a href="https://www.benzinga.com/general/entertainment/24/09/40840076/trump-vs-harris-presidential-debate-viewership-tops-trump-biden-total-but-falls-short-of-re" target="_blank" rel="noreferrer noopener">Trump-Harris debate</a>.</li>
<li>Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) stock was down 7.57%.</li>
<li>KE Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares decreased 7.14%.</li>
<li>Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares lost 5.69% last week following Q3 earnings. Several analysts cut their price forecasts for<a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener"> the stock</a>.</li>
<li>Ryanair Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYAAY#NASDAQ">RYAAY</a>) shares fell 5.38%.</li>
<li>JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) stock lost 5.05% last week after COO tempered analyst outlook.</li>
<li>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) fell 4.87% last week. A JP Morgan analyst maintained Devon Energy with an Overweight rating and lowered the <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $64 to $51</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40869287/chewy-broadcom-and-microstrategy-are-among-top-10-large-cap-stock-gainers-last-week-sep-8-sep-14-are" target="_blank" rel="noreferrer noopener">Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by Lutsenko_Oleksandr on Shutterstock

ADBE

ALLY

BEKE

RYAAY

Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?

Thursday,&nbsp;Moderna&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;unveiled key updates at its annual R&amp;D Day by reducing annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">ten prioritized products</a>.
The company expects R&amp;D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
Oppenheimer downgraded Moderna stock from Outperform to Perform and <a target="_blank" href="https://www.benzinga.com/quote/MRNA/analyst-ratings" rel="noreferrer noopener">removed the price target</a>.
Oppenheimer analyst writes that with a restructured R&amp;D budget, Moderna&#8217;s non-respiratory assets will play a larger role in shaping the pipeline and face increased pressure to reach commercialization.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40754517/modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-show" rel="noreferrer noopener">Moderna&#8217;s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows</a>.
RBC Capital Market decreased the price target from $90 to $75 while maintaining the Sector rating.
The analyst notes the COVID-19 vaccine maker pushed its breaking-even event by two years to 2028.
The analyst remains confident in Moderna&#8217;s cancer vaccine and the potential of its broader platform over the long term. However, near-term challenges continue to be seen, such as declining COVID-19 vaccination rates and the gradual uptake of the respiratory syncytial virus (RSV) vaccine.
Needham&#8217;s analyst highlights substantial commercial and competitive challenges in the respiratory vaccine market across all indications. Investors appear to view cytomegalovirus (CMV) as a less significant commercial opportunity, while the rare disease programs, including MMA and PA, are expected to have only modest peak sales potential, estimated at around $500 million.
The analyst says the INT Oncology program, developed in partnership with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), offers the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39138772/moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-pati" rel="noreferrer noopener">most upside potential</a>. However, progress has been slow, and revenue from this program is unlikely to materialize before 2027 or later. Needham maintains the Hold rating.
William Blair notes that Moderna&#8217;s pattern of issuing high financial expectations, followed by lowered guidance, has negatively impacted the company&#8217;s stock.
Since cutting its 2024 revenue forecast during its second-quarter earnings 2024 call, the stock has <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c" rel="noreferrer noopener">dropped approximately 40%</a>.
The analyst highlights that although Moderna has now pushed back its goal of breaking even to 2028, it will still need to double its revenue from the projected $3.0 billion-$3.5 billion in 2024 to $6.0 billion by 2028 to achieve breakeven along with reduced operating costs and streamlined COGS.
Piper Sandler reiterates the Overweight rating on Moderna but lowers the price target to $115 from $157.
Price Action: MRNA stock closed lower by 2.01% to $68.28 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40858554/chevron-takes-step-towards-greener-shipping-details" target="_blank" rel="noreferrer noopener">Chevron Takes Step Towards Greener Shipping: Details</a>.</li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Analyst Color

Downgrades

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target

16 analysts have shared their evaluations of Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $111.5, along with a high estimate of $214.00 and a low estimate of $60.00. This current average has decreased by 18.06% from the previous average price target of $136.07. 
<img src="https://www.benzinga.com/files/images/story/2024/1726261232_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Moderna by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$178.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Moderna's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>About Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Moderna: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Moderna's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -30.06%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Moderna's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -578.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.43%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.89%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

16 Analysts Have This To Say About Moderna

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 17.75% on an annualized basis producing an average annual return of 31.06%. Currently, Moderna has a market capitalization of $26.16 billion. 
Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $4,004.69 today based on a price of $68.05 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726261215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years

<a href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997">https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997</a>
Even as the Covid wave in Florida continues, Gov. Ron DeSantis' administration is once again advising against the mRNA vaccines: this time in the most vulnerable residents.
In updated guidance for health care providers released Thursday, the Florida Health Department and state Surgeon General Joseph Ladapo questioned the safety and effectiveness of <a href="https://content.govdelivery.com/accounts/FLDOH/bulletins/3b56786">the mRNA Covid vaccines</a> from Pfizer and Moderna, including for older adults and people with underlying health problems. "Any provider concerned about the health risks associated with Covid-19 for patients over the age of 65 or with underlying health conditions should prioritize patient access to non-mRNA Covid-19 vaccines and treatment," according to the state guidance.
Standing in opposition to <a href="https://www.nbcnews.com/health/health-news/new-covid-vaccine-what-know-when-available-timing-rcna167121">advice from federal health agencies</a> and other medical experts about the safety of the Covid vaccines,&nbsp;the Florida Health Department said the recommendation was based on high rates of immunity from prior infections and "currently available data."
Without noting the <a href="https://www.cdc.gov/covid/risk-factors/index.html#:~:text=Older%20adults%20are%20at%20highest,people%20ages%2018%2D29%20years.">high risk of serious Covid infection or hospitalization for older adults</a>, the guidance listed safety concerns for the mRNA vaccines, including the risk of a rare heart condition called myocarditis, as well as the risk of <a href="https://www.nbcnews.com/health/health-news/pots-debilitating-heart-condition-linked-covid-lesser-degree-vaccines-rcna61226">POTS, or postural orthostatic tachycardia syndrome</a>, a debilitating heart condition.&nbsp;
Numerous studies have shown that both Pfizer and Moderna's vaccines are indeed associated with a small <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html">but increased risk of myocarditis</a>. However, most cases occur in young men and most people make a full recovery. Studies have also shown that the risk of myocarditis is much higher with a Covid infection and is often more severe than the vaccine-associated condition.
A study published <a href="https://www.nature.com/articles/s44161-022-00177-8">in Nature Cardiovascular Research</a>​ also found that people diagnosed with Covid are five times more likely to develop POTS after infection than after Covid vaccination, emphasizing the importance of the vaccine.
Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, said the Florida surgeon general's guidance is unnecessarily alarming people about the Covid vaccines.
"It's just such a dangerous game he plays," said Offit, who has served on the FDA's independent vaccine advisory committee. "You only have a roughly 1,000 times greater likelihood of dying [from Covid] if you're over 65 than if you're under 18."
"The mRNA vaccines are remarkably safe," he added.
New doses of the Pfizer and Moderna vaccines were <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently">approved by the Food and Drug Administration</a> in August. They're targeted to the <a href="https://publichealth.jhu.edu/2024/what-to-know-about-covid-flirt-variants">KP.2 version of the steadily mutating virus </a>and should provide good protection against severe illness, hospitalization and death, experts say.&nbsp;
&nbsp;
The United States offers only one <a href="https://www.nbcnews.com/health/health-news/fda-authorizes-novavaxs-updated-covid-vaccine-targeting-jn1-strain-rcna169065">Covid vaccine that isn't mRNA-based: Novavax.</a> Novavax's traditional protein-based shot offers an alternative vaccine technology to mRNA. &nbsp;
In a statement, a Novavax spokesperson said its updated vaccine is now available at thousands of retail and pharmacy locations nationwide.
The Florida Health Department did not immediately respond to a request for additional comment.&nbsp;
Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, called Florida's recommendation "unfortunate," saying it could put older adults and people with underlying health conditions at risk.
"While the vaccine does not protect against infection nearly as well as it once did, there is very good data demonstrating how Covid vaccines can reduce the risk of severe manifestations of the virus in those who are at greatest risk," said Boguch, who has no ties to the vaccine makers.&nbsp;
Covid cases remain high in the U.S. following a summer wave. Wastewater data collected between Aug. 25 and Aug. 31 shows that 23 states -- including Florida -- are reporting "very high" levels of the virus, <a href="https://www.cdc.gov/nwss/rv/COVID19-currentlevels.html">according to the CDC</a>. Emergency department visits and hospitalizations remain <a href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home">elevated as well</a>, although they're showing signs of declining. In Florida nursing homes, after declining from summer highs, Covid infections are ticking up again, <a href="https://www.cdc.gov/nhsn/covid19/ltc-report-overview.html#anchor_1594393304">according to CDC data.&nbsp;</a>
&nbsp;
The CDC <a href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html">currently recommends</a> everyone ages 6 months and older get an updated Covid vaccine this fall from any of the three options.&nbsp;
This isn't the first time Ladapo has ignored CDC guidance. Last year, Ladapo <a href="https://www.nbcnews.com/health/health-news/desantis-administration-advises-no-covid-shots-under-65-rcna104912">also recommended</a> that Florida residents under the age of 65 not get the mRNA Covid vaccines, citing widespread immunity and "questions we have about safety and about effectiveness."
"My judgment is that it's not a good decision for young people and for people who are not at high risk at this point in the pandemic," he said.&nbsp;

"Florida Discourages Use Of mRNA Covid Vaccines In Older Adults; In Updated Guidance To Health Care Providers, Florida Health Officials Advise That "Non-mRNA Covid-19 Vaccines And Treatment" Should Be Prioritized" - NBC News

B of A Securities analyst Geoff Meacham maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Neutral and lowers the price target from $130 to $110.

B of A Securities Maintains Neutral on Moderna, Lowers Price Target to $110

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="http://benzinga.com/analyst-stock-ratings"> analyst ratings page</a>.
<ul>
<li>Wells Fargo cut the price target for Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from $15 to $13. Wells Fargo analyst Dori Kesten maintained an Equal-Weight rating. Pebblebrook Hotel Trust shares rose 1.5% to trade at $12.98 on Friday. S<a href="https://www.benzinga.com/quote/PEB/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from $70 to $60. TD Cowen analyst Tyler Van Buren maintained a Hold rating. Moderna shares fell 4.9% to trade at $66.25 on Friday. <a href="https://www.benzinga.com/quote/mrna/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities cut Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) price target from $117 to $112. Truist Securities analyst Richard Newitter reiterated a Hold rating. Zimmer Biomet shares gained 1.8% to trade at $107.06 on Friday. <a href="https://www.benzinga.com/quote/zbh/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim raised Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) price target from $185 to $200. Guggenheim analyst John Difucci maintained a Buy rating. Oracle shares rose 1% to trade at $162.87 on Friday. <a href="https://www.benzinga.com/quote/orcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) from $53 to $60. Goldman Sachs analyst Alexander Blostein maintained a Buy rating. TPG shares gained 3% to close at $55.55 on Friday. S<a href="https://www.benzinga.com/quote/tpg/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>UBS boosted CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) price target from $53 to $54. UBS analyst Michael Goldsmith downgraded the stock from Buy to Neutral. CubeSmart shares fell 0.2% to trade at $53.81 on Friday. <a href="https://www.benzinga.com/quote/cube/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>Stifel cut Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) price target from $121 to $103. Stifel analyst Steve Wieczynski maintained a Buy rating. Wynn Resorts shares rose 3.6% to trade at $79.07 on Friday. <a href="https://www.benzinga.com/quote/wynn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Nabors Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) from $110 to $75. Citigroup analyst Scott Gruber downgraded the stock from Buy to Neutral. Nabors Industries shares rose 0.5% to trade at $65.41 on Friday. <a href="https://www.benzinga.com/quote/nbr/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays slashed Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) price target from $181 to $133. Barclays analyst George Wang downgraded the stock from Equal-Weight to Underweight. Garmin shares fell 6.2% to trade at $170.74 on Friday. <a href="https://www.benzinga.com/quote/grmn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $62 to $63. Evercore ISI Group analyst Michael Montani maintained an Outperform rating. Kroger shares rose 1.1% to trade at $55.81 on Friday. <a href="https://www.benzinga.com/quote/kr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40853112/ionq-is-losing-too-much-money-while-this-tech-stock-is-real-deal-jim-cramer">IonQ Is Losing &#8216;Too Much Money&#8217; While This Tech Stock Is &#8216;Real Deal&#8217;: Jim Cramer</a></li>
</ul>

CUBE

GRMN

ORCL

WYNN

Oracle To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Friday

TD Cowen analyst Tyler Van Buren maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Hold and lowers the price target from $70 to $60.

TD Cowen Maintains Hold on Moderna, Lowers Price Target to $60

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Sector Perform and lowers the price target from $90 to $75.

RBC Capital Maintains Sector Perform on Moderna, Lowers Price Target to $75

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024.

Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14

Notable analyst calls this week: Oracle, Moderna and Costco among top picks

Moderna: Cutting Costs At Just The Worst Time

Evercore ISI analyst Cory Kasimov maintained a Hold rating on Moderna (MRNA – Research Report) on September 13 and set a price target of $105.00. T...

Evercore ISI Keeps Their Hold Rating on Moderna (MRNA)

A class action lawsuit was filed against Moderna, Inc. ($MRNA) by Levi & Korsinsky on August 9, 2024. The plaintiffs (shareholders) alleged that th...

Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on September 13. Analyst Mani Foroohar from...

Moderna's Financial Forecast Dims: Sell Recommendation Amidst R&D and Regulatory Hurdles

How is VOO stock faring? The Vanguard S&P 500 ETF is up 2.76% in the past five days and has risen 28.11% over the past year. According to TipRanks'...

VOO ETF Update, 9/16/2024

Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month

Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system.

Momentum Investing Gives You An Edge, Until It Doesn't

UBS highlights 30 stocks poised for potential moves after the Fed's expected rate cut

ALLE

BBWI

CHTR

COST

CTAS

CTLT

CVNA

DELL

DLTR

ETSY

FULC

MSFT

MTCH

MTUM

NVDA

QRVO

ROKU

SBAC

SOLV

TSLA

UBSFF

ULTA

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Lost Money on Moderna, Inc. (MRNA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline

MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit

Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA

Faruqi & Faruqi Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join – Contact The Gross Law Firm

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Moderna

Moderna (MRNA) Forecast

Moderna (NASDAQ:MRNA) Stock, Quote.Headers.trade-ideas